PEGYLATED eMIP, METHOD FOR PRODUCING THE SAME AND CANCER THERAPEUTIC AGENT USING THE SAME

PROBLEM TO BE SOLVED: To provide a new PEGylated eMIP desirable as a cancer therapeutic agent and an immunopotentiator obtained by chemically modifying eMIP being a mutant of MIP-1α (Macrophage Inflammatory Protein-1α) a prescribed polyethylene glycol (PEG), a method for producing the same and a cancer therapeutic agent comprising a PEGylated eMIP as an active ingredient. SOLUTION: The PEGylated eMIP is obtained by chemically modifying an eMIP being a mutant of MIP-1α with a straight-chain or branched polyethylene glycol (PEG) having an average molecular weight of 10,000-30,000. The method for producing a PEGylated eMIP in which one PEG group is introduced into one molecule of eMIP includes using a maleimide PEG having an average molecular weight of 10,000-30,000 as a PEGylating agent and reacting an eMIP with the maleimide PEG in the reaction ratio of 1-1.5 times based on the amino group of the eMIP and under a basic condition. The cancer therapeutic agent comprises a PEGylated eMIP as an active ingredient. COPYRIGHT: (C)2011,JPO&INPIT